종근당

185750KOSPI의약품 제조업

50.8 / 100

Reference Date: 2026-07-24

Financial Score16.0 / 40

News Sentiment17.8 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE significantly exceeds the industry average but the high debt ratio poses financial risk. Roughly flat over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Jonggun Pharm is a major South Korean pharmaceutical company established in 1941, specializing in both prescription and over-the-counter drugs. It invests 9-11% of its sales in R&D, focusing on new drug development and biosimilars, with key products including the anticancer drug 'Camtovel' and the diabetes treatment 'Duvie'. As of 2023, it holds approximately 5% of the domestic pharmaceutical market share.

Number of Employees

2,304people

Average Salary

79.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

11.48Industry Average 11.233.0Point

Higher than industry avg (caution)

PBR

0.93Industry Average 0.812.5Point

Higher than industry avg (caution)

ROE

8.18Industry Average 4.017.0Point

2.0x industry avg (excellent)

Debt Ratio

27.61Industry Average 12.430.0Point

2.2x industry avg (risky)

Trend 2023~20253.5 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲0.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼39.3% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 17.0% (declining, 3yr)

Detailed News Sentiment

25 totalPositive 15Neutral 5Negative 5Average Sentiment Score 71.2

Positive
종근당, 혁신 신약 개발 교두보 마련…글로벌 시장 정조준
종근당이 혁신적인 신약 개발을 위한 전담 조직을 출범시키고 글로벌 시장 진출을 가속화함으로써 긍정적인 전망을 제공합니다.
Negative
종근당, 영업이익 불안정해…목표가↓-iM증권
종근당의 영업이익 감소로 인해 목표주가가 하락하며 부정적인 시장 반응이 예상된다.
Positive
에이프릴, 큐리진 2대 주주로…차세대 RNA치료제 본격 진출
종근당의 자회사 에이프릴바이오의 RNA 치료제 분야 진출로 인해 관련 산업 내 긍정적 관심 증가.

Detailed Momentum

52-week position1.0Point

Near 52w low (10%, downtrend)

Current 67,500Won52-week high 97,70052-week low 64,100

1-month return3.0Point

1m 0.3% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral공정거래자율준수프로그램운영현황(안내공시)2026-07-22
Neutral주식등의대량보유상황보고서(일반)2026-07-16
Neutral주식등의대량보유상황보고서(약식)2026-07-01
Neutral지속가능경영보고서등관련사항(자율공시)2026-06-30
Neutral주식등의대량보유상황보고서(약식)2026-06-26